Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Delivery
Formulation of oral heparin selected after successful clinical study
September 9th, 2004
Emisphere Technologies, Inc., (EMIS) has selected a soft-gelatin capsule formulation of unfractionated heparin (UFH), an antithrombotic/anticoagulant, that achieved clinically significant delivery of heparin. This formulation was chosen after the evaluation of results from a clinical trial comparing various oral dosage formulations of EMISPHERE Heparin/SNAC to the company's liquid UFH formulation, which was previously tested in a phase III trial. With this new formulation, the company plans to initiate discussions with the U.S. Food and Drug Administration to outline a clinical development program, comparing one of the new oral UFH solid dosage forms with the currently...
Source: Blood Weekly (2004-09-09)
|
